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A B S T R A C T
CTX-M b-lactamases have been reported world-
wide since their first description in the early
1990s, and are now endemic in some countries.
This report describes an isolate of Escherichia coli
producing CTX-M-14 that was recovered from the
faecal sample of a healthy subject in Portugal
without recent hospital or antibiotic exposure.
The presence of ISEcp1, 42 nucleotides upstream
of blaCTX-M-14, and its association with a 100-kb
conjugative plasmid, might result in wider dis-
semination of this enzyme in community and
hospital environments in Portugal.
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The CTX-M b-lactamases are a growing group of
class A extended-spectrum b-lactamases that are
distinguished from TEM and SHV b-lactamases
by their much greater hydrolytic activity against
cefotaxime than against ceftazidime [1]. Members
of this family fit within six major groups (exem-
plified by CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-
9, CTX-M-25 and Toho-2) on the basis of their
nucleotide and deduced amino-acid sequence
similarities [1]. Members of the different clusters
show differences of 10–30% in their amino-acid
sequences, while variants of the same cluster
show minor differences [1] (http://www.lahey.
org/studies/webt.htm). The blaCTX-M genes are
generally located on transferable plasmids of
variable size, and some have been shown to be
located within unusual class 1 integrons [1]. Two
different elements have been thought to play a
role in the mobilisation and expression of the
blaCTX-M genes: first, the ISEcp1 element, an
insertion sequence (IS) located upstream of many
blaCTX-M genes; and second, ORF513, a putative
transposase associated with unusual integrons
that might be involved in the acquisition of
different resistance genes. Finally, IS903 has been
found downstream of some blaCTX-M genes, sug-
gesting a role in their dissemination [1–3].
The CTX-M enzymes, described first in the
early 1990s in South America and Europe, have
spread worldwide, and are now endemic in
South America, Japan, eastern Europe and Spain
[1,4–6]. In July 2003, a cefotaxime-resistant
isolate of Escherichia coli (EC-C498) was isolated
in Porto during a surveillance study of exten-
ded-spectrum b-lactamase-producing isolates in
northern Portugal. This isolate was recovered
from the faecal sample of a female, aged
76 years, without hospital or antibiotic exposure
in the 3-month period preceding collection of
the sample. MICs of b-lactams were determined
with Etests (AB Biodisk, Solna, Sweden), used
according to the procedures recommended by
the supplier. Susceptibility to non-b-lactam anti-
microbial agents was determined by the disk
diffusion method according to National Com-
mittee for Clinical Laboratory Standards guide-
lines [7]. Characterisation of b-lactamases was
performed by isoelectric focusing, followed
by PCR amplification with primers to amplify
the blaTEM, blaSHV, blaCTX-M-9 and blaCTX-M-10
genes, and sequencing of the products obtained
[8].
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Conjugation experiments were performed by
the filter-mating method, with E. coli BM21R
(nalidixic acid- and rifampicin-resistant, lactose-
positive, and plasmid-free) as the recipient strain
[8]. Mating experiments were performed over-
night at 37C, and transconjugants were selected
on MacConkey agar plates containing cefotaxime
(2 mg ⁄L) and rifampicin (100 mg ⁄L). Plasmid
DNA from the wild-type strain and transconju-
gants was obtained using a QIAgen Plasmid Midi
Kit (QIAgen, Hilden, Germany). Plasmid DNA
was characterised by digestion with BamHI,
HindIII and EcoRI restriction enzymes [4]. The
presence of ISEcp1 and IS903 upstream and
downstream of blaCTX-M-14, respectively, was
determined using primers ISEcp1-F (5¢-AT-
CTAACATCAAATGCAGG-3¢) and ISEcp1-R (5¢-
AGACTGCTTCTCACACAT-3¢) to amplify a
1391-bp intragenic sequence of ISEcp1, primers
ISEcp1-M (5¢-TGTCGTATCTGCGCGTACTGAA-
3¢) and blaCTX-M-9-Rf (5¢-CCGTTGCACTCTCTTT-
GTCA-3¢) to demonstrate the link between ISEcp1
and blaCTX-M-14, and primers IS903-A (5¢-CATAT-
GAAATCATCTGCGC-3¢) and IS903-B (5¢-CC-
GTAGCGGGTTGTGTTTTC-3¢) to amplify an
intragenic sequence of IS903D transposase [9].
The MICs of different b-lactam antibiotics for
E. coli strain EC-C498 are shown in Table 1.
EC-C498 was also resistant to streptomycin, nal-
idixic acid, ciprofloxacin, sulphonamides, tetra-
cycline and chloramphenicol. The corresponding
transconjugant had MICs of some b-lactams that
were lower than those for the clinical isolate, but
also acquired resistance to chloramphenicol. Plas-
mid analysis revealed the presence of three
plasmids (c. 100 kb, 110 kb and 135 kb) in the
parent strain, with the 100-kb plasmid also being
present in the transconjugant. Plasmid finger-
printing analysis did not reveal any relationship
between several plasmids containing blaCTX-M-14
recovered in Spain and the plasmid isolated in the
present study (results not shown). PCR and
isoelectric focusing detected the presence of
CTX-M-9-like (pI 8.0) and TEM (pI 5.4) b-lacta-
mases in the parent strain, but only the CTX-M-9-
like enzyme was detected in the transconjugant.
No PCR products were obtained with primers
specific for blaSHV or blaCTX-M-10. Sequencing
identified the CTX-M-9-like enzyme as CTX-M-
14, which differed from CTX-M-9 by the amino-
acid substitution A231V. As described previously
for CTX-M-14-producing isolates from France,
China and Spain, the presence of ISEcp1 was
detected 42 nucleotides upstream of blaCTX-M-14
[1,4,6,10,11].
The present report is the first description of a
CTX-M b-lactamase-producing isolate of Entero-
bacteriaceae from Portugal. The fact that EC-C498
was isolated from the faecal sample of a healthy
person without recent hospital (including long-
term care facilities) or antibiotic exposure indi-
cates the possibility of unrecognised widespread
dissemination of these isolates within the normal
population in Portugal. The emergence and
spread of organisms producing CTX-M-14 has
been reported in Asian, European and South
American hospitals [1,4,8,10–12], with Spain
being one of the countries where blaCTX-M-14 is
disseminated widely in both community and
hospital environments [4–6,8,13]. The description
of ISEcp1-blaCTX-M-14 in different plasmids from
isolates recovered in several countries suggests
multiple lateral transfer events of a successful
transposable element into different backgrounds.
Further surveillance studies are required to
investigate the prevalence and possible dissemin-
ation of CTX-M-producing organisms in hospitals
and the community in Portugal.





phenotypeAMX AMC PP PTc TI TLc CE CTX CTX-CL CAZ CAZ-CL CEP CEP-CL FOX
E. coli C498 > 256 4 > 256 8 > 256 16 > 256 > 256 0.06 1 0.06 4 £ 0.06 4 Nal, Cip, St, Sul, Te, Chl
E. coli C498 ⁄BM21R > 256 4 128 8 > 256 4 > 256 4 0.03 0.5 £ 0.06 1 £ 0.06 2 Nal, Chl
E. coli BM21R 1 1 0.5 0.5 1 0.5 2 0.016 £ 0.016 0.06 £ 0.06 0.008 £ 0.06 2 Nal, Rif
AMX, amoxycillin; AMC, amoxycillin–clavulanic acid; PP, piperacillin; PTc, piperacillin–tazobactam; TI, ticarcillin; TLc, ticarcillin–clavulanic acid; CE, cephalothin; CTX,
cefotaxime; CTX-CL, cefotaxime–clavulanic acid; CAZ, ceftazidime; CAZ-CL, ceftazidime–clavulanic acid; CEP, cefepime; CEP-CL, cefepime–clavulanic acid; FOX, cefoxitin;
Nal, nalidixic acid; Cip, ciprofloxacin; St, streptomycin; Sul, sulphonamides; Te, tetracycline; Chl, chloramphenicol; Rif, rifampicin.
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First identification of an Escherichia coli
clinical isolate producing both metallo-
b-lactamase VIM-2 and extended-spectrum
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A B S T R A C T
An Escherichia coli strain with decreased suscepti-
bility to carbapenems was isolated from a hospi-
talised patient in Athens, Greece. The strain was
resistant to all b-lactams, including aztreonam,
whereas the MIC of imipenem and meropenem
was 0.5 mg ⁄L. A positive EDTA–disk synergy test
suggested the production of ametallo-b-lactamase.
PCR experiments revealed the presence of the
blaVIM-2, blaIBC-1 and blaTEM-1 genes. Resistance to
b-lactamswasnot transferable by conjugation. This
is the first report of a clinical isolate of E. coli pro-
ducingVIM-2, and the first report of the coexistence
of blaVIM-2 and blaIBC-1 in a single clinical isolate.
Keywords blaIBC-1, blaVIM-2, carbapenemase, Escheri-
chia coli, metallo-b-lactamase, resistance
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Metallo-b-lactamases (MBLs) of the VIM type are
integron-borne enzymes that can be either chrom-
osomally-encoded or plasmid-mediated. With
the exception of aztreonam, they hydrolyse all
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